Kangshun Zhu, Dr.
Second Affiliated Hospital of Guangzhou Medical University
7
4
4
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Gao-Jun Teng, MD
Zhongda Hospital
Shared therapeutic areas:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Ming Shi, MD
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Saleh K Saleh, MD
Minia University
Shared therapeutic areas:
shiow-ching shun, PhD
National Taiwan University
Shared therapeutic areas:
Peng Wang, MD
Fudan University
Shared therapeutic areas:
Ping Liang, doctor
Chinese PLA General Hospital
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
DEB-TACE+HAIC vs. HAIC for Large HCC
Donafenib Plus Sintilimab for Advanced HCC
Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
All 7 trials loaded